RESUMO
Objective To investigate the relationship between telomere DNA length of peripheral leukocytes and tumor type and prognosis in non-small cell lung cancer ( NSCLC) . Methods From June 2016 to April 2017,the thoracic surgery department of Baoding First Central Hospital,Hebei Province was included in the study. The patients with lung cancer and TNM stage were confirmed by pathological examination,excluding the patients with unknown general records and lost visits. Finally,55 patients were included,including 35 patients in adenocarcinoma group and 20 patients in other non-small cell lung cancer group. The telomere DNA length of peripheral blood leukocytes in patients with non-small cell lung cancer was detected by real-time fluorescence quantitative PCR, and the survival of patients was followed up to analyze the relationship between telomere DNA length of peripheral blood leukocytes and tumor pathological type and prognosis. Results The telomere DNA length (T／s) (1. 98±0. 69) of adenocarcinoma group was larger than that of other non-small cell lung cancer group (1. 43±0. 67),P＝0. 007; there was no significant difference in the telomere DNA length of peripheral blood leukocytes in patients with different TNM stages. According to the length of telomere DNA in peripheral blood, the average survival time of short telomere group was 17. 149 months(95%CI＝14. 696～19. 602),which was significantly lower than that of long telomere group (30. 857 months,95%CI＝28. 515～33. 199),the difference was statistically significant (P＝0. 001); Cox proportional risk regression analysis showed that: telomere DNA length (P＝0. 041), tumor stage (P＝0. 007) were independent risk factors for prognosis of patients. Conclusion Telomere DNA length of peripheral blood leukocytes in patients with lung adenocarcinoma is longer than that of other non-small cell lung cancer, and TNM stage and telomere DNA length of peripheral blood leukocytes are independent risk factors for prognosis of non-small cell lung cancer.
RESUMO
Objective To analyze and evaluate the relationship between hepoatocelluar carcinoma incidence and hepatitis B e antigen (HBeAg) expression in choronic hepatitis B (CHB) patients with long-term treatment of nucleoside analogue therapy.Methods The clinical data of 56 CHB patients with long-term treatment of nucleoside analogue therapy except for hepoatocelluar carcinoma (experimental group)were summarized retrospectively,and all patients underwent anti-viral therapy with no less than 5 years.The clinical data of 56 CHB patients without anti-viral therapy in the same period (control group) were collected.The risk factors of hepoatocelluar carcinoma were analyzed.Results The incidence of hepoatocelluar caroinoma was 7.14％ (4/56) in experimental group and 19.64％ (11/56) in control group,and there was significant difference (P ＜ 0.05).The incidence of hepoatocelluar carcinoma was 0 in patients with positive HBeAg without cirrhosis (36 cases) in experimental group and 1/8 in patients with negative HBeAg without cirrhosis in experimental group,and there was significant difference (P＜ 0.05).Conclusions Long-term treatment of nucleoside analogue therapy can reduce but bot eliminate the hepatocellular carcinoma risk in patients with CHB,especially in those with negative HBeAg.HBeAg negativity is a significant risk factor for the development of hepallerular carcinoma in CHB patients without liver cirrhosis.